Active ingredients in Chinese medicines promoting blood circulation as Na+/K+ -ATPase inhibitors
- PMID: 21293466
- PMCID: PMC4009935
- DOI: 10.1038/aps.2010.197
Active ingredients in Chinese medicines promoting blood circulation as Na+/K+ -ATPase inhibitors
Abstract
The positive inotropic effect of cardiac glycosides lies in their reversible inhibition on the membrane-bound Na(+)/K(+)-ATPase in human myocardium. Steroid-like compounds containing a core structure similar to cardiac glycosides are found in many Chinese medicines conventionally used for promoting blood circulation. Some of them are demonstrated to be Na(+)/K(+)-ATPase inhibitors and thus putatively responsible for their therapeutic effects via the same molecular mechanism as cardiac glycosides. On the other hand, magnesium lithospermate B of danshen is also proposed to exert its cardiac therapeutic effect by effectively inhibiting Na(+)/K(+)-ATPase. Theoretical modeling suggests that the number of hydrogen bonds and the strength of hydrophobic interaction between the effective ingredients of various medicines and residues around the binding pocket of Na(+)/K(+)-ATPase are crucial for the inhibitory potency of these active ingredients. Ginsenosides, the active ingredients in ginseng and sanqi, substantially inhibit Na(+)/K(+)-ATPase when sugar moieties are attached only to the C-3 position of their steroid-like structure, equivalent to the sugar position in cardiac glycosides. Their inhibitory potency is abolished, however, when sugar moieties are linked to C-6 or C-20 position of the steroid nucleus; presumably, these sugar attachments lead to steric hindrance for the entrance of ginsenosides into the binding pocket of Na(+)/K(+)-ATPase. Neuroprotective effects of cardiac glycosides, several steroid-like compounds, and magnesium lithospermate B against ischemic stroke have been accordingly observed in a cortical brain slice-based assay model, and cumulative data support that effective inhibitors of Na(+)/K(+)-ATPase in the brain could be potential drugs for the treatment of ischemic stroke.
Figures
References
-
- Boxer R, Yang SX, Hager WD. Congestive heart failure and the elderly. Conn Med. 2003;67:497–503. - PubMed
-
- Haustein KO. Cardiotoxicity of digitalis. Arch Toxicol Suppl. 1986;9:197–204. - PubMed
-
- Koren G, Woodland C, Ito S. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Vet Hum Toxicol. 1998;40:45–6. - PubMed
-
- Vivo RP, Krim SR, Perez J, Inklab M, Tenner T, Jr, Hodgson J. Digoxin: current use and approach to toxicity. Am J Med Sci. 2008;336:423–8. - PubMed
-
- Gong X, Sucher NJ. Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. Phytomedicine. 2002;9:478–84. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
